Eureka Therapeutics is a clinical-stage biotechnology company headquartered in the San Francisco Bay Area (Emeryville, Calif.) focused on developing novel T cell therapies for solid tumors. Its core technologies include the proprietary ARTEMIS® AbTCR T-cell receptor platform and the E-ALPHA® antibody discovery platform for discovery and development of potentially safer and more effective T cell therapies. The company’s lead asset, ET140202, is in a Phase I/II U.S. multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC). Eureka is advancing an anti-AFP ARTEMIS® Phase I/II clinical trial in the United States and is continuing development of its TCR-mimic and antibody-TCR ARTEMIS® programs. TCR-mimic antibodies are designed to recognize tumor-specific peptide/MHC complexes, enabling targeting of intracellular cancer-associated proteins that are not accessible to conventional antibodies or small molecules. The company will use proceeds from the Series E to accelerate these programs and clinical development. Eureka Therapeutics is a clinical-stage biotechnology company based in Emeryville, California, focused on improving the safety profile of T cell therapies and developing novel T cell therapies for hematological malignancies and solid tumors. Its core technologies include the proprietary ARTEMIS™ T cell receptor platform and the E-ALPHA® phage display library for discovery and engineering of human antibodies against intracellular targets via the MHC class I complex. The company is developing a pipeline targeting intracellular oncogenes as well as cell-surface antigens, with lead candidate ET190L1-ARTEMIS™ T cells in clinical development for relapsed and refractory CD19+ Non-Hodgkin Lymphoma. In November 2017 the U.S. FDA approved its IND and authorized a Phase I trial for ET190L1-ARTEMIS™, and Eureka expected to enroll the first patient at Duke University in Q1 2018. Eureka intends to use the Series D proceeds to advance ET190L1-ARTEMIS™ in that indication and to accelerate its broader immunotherapy pipeline against other hematological and solid tumors. The company is led by President and CEO Cheng Liu, PhD. Eureka Therapeutics is a Bay Area cancer immunotherapy company engineering monoclonal antibodies to mimic T cell receptors and recognize peptides from intracellular proteins presented on MHC. Its approach aims to target the roughly 90% of cancer-specific targets that are intracellular and traditionally considered undruggable. The company’s antibodies are designed to galvanize a patient’s immune system to attack and destroy cancer cells presenting those peptides. Eureka has a preclinical monoclonal antibody, ESK1, that targets the intracellular protein WT1 and was co-developed with Memorial Sloan‑Kettering Cancer Center. Earlier this year the company signed a license agreement with Novartis to develop and commercialize ESK1. Financially, Eureka recently completed a $21 million Series C to further advance its intracellular-targeting antibody programs. Eureka Therapeutics develops antibodies used to treat cancer. The company raised $6 million in a second-round financing to continue development of those antibodies. It also conducts outsourced antibody research services for other firms. The firm is based in Emeryville, Calif. Eureka previously completed a $1.6 million first round in 2006. The company is using the new financing to advance its antibody development programs.

Total raised

$132M

Funding rounds

4

Latest round

Series E

Latest activity

Mar 2020